Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 360, Issue 6, 1999, Pages 719-720

  Russ, Hermann ^a   Müller, Thomas ^b   Woitalla, Dirk ^b   Rahbar, Afshin ^b   Hahn, Jürgen ^a   Kuhn, Wilfried ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Cerebrospinal fluid; Parkinson's disease; Tolcapone

Indexed keywords

BENSERAZIDE; CATECHOL METHYLTRANSFERASE; LEVODOPA; TOLCAPONE;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DETERMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUMBAR PUNCTURE; MALE; PARKINSON DISEASE;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOPHENONES; BLOOD-BRAIN BARRIER; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; NITROPHENOLS; PARKINSON DISEASE;

EID: 0033401630     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002109900168     Document Type: Article

References (11)

1. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G, on behalf of the study investigators (1997) Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 63:421-428
2. Kuhn W, Woitalla D, Gerlach M, Russ H, Müller T (1998) Tolcapone and neurotoxicity in Parkinson's disease. Lancet 352: 1313-1314
3. Müller T, Kuhn W, Przuntek H (1993) Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders? J Neural Transm 92: 187-195
4. Nic a Bhaird N, Goldberg R, Tipton KF (1990) Catechol-o-methyltransferase and its role in catecholamine metabolism. Adv Neurol 53:489-495
5. Offen D, Panet H, Melamed E (1999) Catechol-O-methyltransferase reduced levodopa toxicity in PC12 cells: implications for treatment of Parkinson's disease. Ann Neurol 46:459
6. Timm Y, Erdin R (1992) Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 593:63-68
7. Toghi H, Abe T, Yamazaki K, Saheki M, Takahashi S, Tsukamoto Y (1995) Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 192: 165-168
8. Waters CH, Kurth M, Bailey P, Shulman LM, LeWitt P, Dorflinger E, Deptula D, Pedder S, and the Tolcapone Stable Study Group (1997) Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 49:665-671
9. Werner P, Di Rocco A, Rogers J, Rempel N (1999) Methionine, dimethionine and SAM protect dopamine neurons against 1-dopa toxicity. Parkinson Relat Disord [Suppl] 5:44 (P-MO-165)
10. Xie T, Ho SL, Ramsden D (1998) Catechol-O-methyltransferase inhibitors in Parkinson's disease. Lancet 351:1966
11. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, Da Prada M (1993) Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain: preclinical and clinical findings. Adv Neurol 53:641-647